AnaptysBio Inc $ 25.73 -0.19 (-0.73%)
Volume:
171,965
Avg Vol (1m):
316,805
Market Cap $:
702.52 Mil
Enterprise Value $:
324.64 Mil
P/E (TTM):
0.00
P/B:
1.84
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 20.27 | ||
| Beneish M-Score | -2.91 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -386.48 | ||
| Net Margin % | -352.63 | ||
| ROE % | -19.72 | ||
| ROA % | -18.49 | ||
| ROC (Joel Greenblatt) % | -5110.71 | ||
| 3-Year Revenue Growth Rate | -31.5 | ||
| 3-Year EBITDA Growth Rate | -162.5 | ||
| 3-Year EPS without NRI Growth Rate | -148.5 |
ANAB
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.84 | ||
| PS Ratio | 38.98 | ||
| EV-to-EBIT | -4.02 | ||
| EV-to-EBITDA | -4.05 | ||
| EV-to-Revenue | 18.04 | ||
| Current Ratio | 19.1 | ||
| Quick Ratio | 19.1 | ||
| Days Sales Outstanding | 79.35 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.84 | ||
| Earnings Yield (Greenblatt) % | -24.88 |